Studies related to Symptoms of Rheumatoid Arthritis and Boron

The Adjuvant Use Of Calcium Fructoborate And Borax With Etanercept In Patients With Rheumatoid Arthritis: Pilot Study

Effect Decrease
Values Mean and SD. Swollen joint counts: Placebo: before 4.7 (2.5), after 4.2 (1.6). Sodium tetraborate: before 4.3 (2.6), after 3.0 (1.8). Calcium fructoborate: before 3.7 (1.8), after 2.2 (1.9). Tender joint counts: Placebo: before 10.6 (4.1), after 9.3 (5.3). Sodium tetraborate: before 10.5 (4.7), after 6.6 (5.4). Calcium fructoborate: before 10.6 (3.8), after 7.0 (3.3). VAS (cm). Placebo: before 6.7 (1.3), after 5.6 (1.1). Sodium tetraborate: before 6.9 (1.7), after 6.9 (1.7). Calcium fructoborate: before 7.2 (1.3), after 4.8 (1.0). EGA Placebo: before 6.3 (0.8), after 5.6 (1.1). Sodium tetraborate: before 6.3 (1.3), after 4.8 (1.5). Calcium fructoborate: before 6.5 (1.0), after 4.2 (1.0).
Trial Design Randomized trial
Trial Length 1-6 months
Number of Subjects 80
Sex Both Genders
Notes for this study:
In a randomized, double-blind, placebo-controlled trial 80 participants with rheumatoid arthritis were allocated to take 220 mg of calcium fructoborate, 55 mg of sodium tetraborate, both containing 6 mg of elemental boron, or placebo for 8 weeks. Participants were all taking etanercept. Tenderness and swollenness of joints, as well as pain on a visual analog scale and evaluator's global assessment (EGA) were reduced more in the boron groups than the placebo group, without statistically significant differences between them.

Erythrocyte sedimention rate, c-reactive protein, IL-1a, and IL-6 were all notably decreased more by boron than placebo.